相关实验视频

Updated: Jan 9, 2026

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

和智力障碍的成年患者的塞诺巴

David Steinbart¹, Rebekka Geelhaar², Rebekka Lehmann²

¹Epilepsy-Center Berlin-Brandenburg, Institute for Diagnostics of Epilepsy, Herzbergstr. 79, 10365 Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Department of Neurology, Augustenburger Platz 1, 13353 Berlin, Germany.

|December 6, 2025

概括

塞诺巴 (CNB) 在智力障碍和 (PWE+ID) 的成年人中有效且耐受良好,表现与没有ID的成年人相似. 这项研究证实了CNB的说法.

科学领域:

的研究研究.
智力障碍智力障碍是一种智力障碍.
药理疗效药理疗效药理疗效

背景情况:

在智力障碍 (ID) 患者中非常普遍,通常会带来治疗挑战.
患有和智障 (PWE+ID) 的人在临床研究中代表性不足.
辅助性赛诺巴酸 (CNB) 在治疗中表现有前途.

研究的目的:

评估成年患者和智力障碍患者 (PWE+ID) 辅助赛诺巴 (CNB) 的疗效和耐受性.
为了比较PWE+ID中的CNB结果与患有但没有ID的患者 (PWE-ID).
评估这些人群中与CNB相关的保留率,发作减少和不良事件.

主要方法:

对108名患有的成年患者 (51名患有) 进行了回顾性研究,开始接受CNB治疗.
每季度的电话调查评估了在12个月内保持,发作的结果 (3个月的比较) 和不良事件.
统计分析包括千平方,曼-惠特尼U测试和贝叶斯的非劣势分析.

主要成果:

在6个月和12个月的PWE+ID和PWE-ID之间,保留率是可比的 (75%与12个月的70%对比).
50%的应答率在6个月和12个月时相似 (53%对53%在12个月).
不良事件是相似的 (59%对60%),疲劳和头是最常见的;停药率是相似的 (24%对28%).

结论:

辅助赛诺巴 (CNB) 在患有和智力障碍 (PWE+ID) 的成年患者中和没有ID的患者中表现出相似的疗效和耐受性.
贝叶斯分析支持CNB在PWE+ID中对于保留率和响应率的非劣势.
在智力障碍的成年人中,CNB是一种可行的治疗的选择.

关键词:

50%的响应率是响应者.不良事件不良事件不良事件药物耐药性的治疗方法留存率是指保留的比例.夺取自由,夺取自己的自由.

更多相关视频

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...